Valuation: Actinium Pharmaceuticals, Inc.

Market Cap 2.54Cr 2.21Cr 2.06Cr 1.89Cr 3.57Cr 241.74Cr 3.61Cr 24Cr 9.48Cr 120.84Cr 9.54Cr 9.33Cr 400.41Cr P/E 2026 *
-0.96x
P/E 2027 * -1.45x
Enterprise Value 2.54Cr 2.21Cr 2.06Cr 1.89Cr 3.57Cr 241.74Cr 3.61Cr 24Cr 9.48Cr 120.84Cr 9.54Cr 9.33Cr 400.41Cr EV / Sales 2026 *
-
EV / Sales 2027 * 1.97x
Free-Float
97.65%
Yield 2026 *
-
Yield 2027 * -
03/06 Actinium Pharmaceuticals Presents New Data on Atnm-400 Demonstrating Potent Activity in Prostate Cancer Models Resistant to All Three Approved Androgen Receptor Inhibitors CI
01/06 Actinium Pharmaceuticals, Inc. Appoints Steffen Heeger as Chief Medical Officer CI
01/06 Actinium Pharmaceuticals Presents New Radiochemistry Data Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates CI
30/05 Actinium Pharmaceuticals - receives two Canadian patent allowances for Actimab-A and Iomab-Act programs RE
30/05 Actinium Pharmaceuticals Receives Patent Allowances for Actimab-A and Iomab-Act Programs in Canada CI
09/05 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
06/05 Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of Atnm-400 Across Lung and Prostate Cancer and Radioconjugate Optimization CI
22/04 Actinium Pharmaceuticals, Inc. Highlights Transcriptional Reprogramming As Key Mechanism Underpinning Mutation-Agnostic Activity Of Actimab-A In AML CI
22/04 Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models At the 2026 American Association of Cancer Research Annual Meeting CI
07/04 Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for Atnm-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in Aml CI
31/03 Actinium Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
17/02 CNS Pharmaceuticals, Inc. Announces Chief Financial Officer Changes, Effective March 2, 2026 CI
14/02 Actinium Pharmaceuticals, Inc. Announces Executive Changes, Effective as of February 27, 2026 CI
1 day-0.18%
1 week-6.52%
Current month-3.21%
1 month-17.43%
3 months-32.50%
6 months-30.17%
Current year-40.44%
1 week 0.81
Extreme 0.81
0.86
1 month 0.81
Extreme 0.8068
1.05
Current year 0.81
Extreme 0.8068
1.53
1 year 0.81
Extreme 0.8068
1.81
3 years 0.81
Extreme 0.8068
10.24
5 years 0.81
Extreme 0.8068
15.12
10 years 0.81
Extreme 0.8068
64.5
Manager TitleAgeSince
Chief Executive Officer 62 09/06/2017
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 01/01/2025
Director TitleAgeSince
Director/Board Member 71 01/01/2008
Chairman 62 01/10/2013
Director/Board Member 68 08/11/2013
Date Insider Type Main position Quantity % Market Cap.
18/08/25 Tax

Chief Executive Officer

1,20,900 0.3876%
31/03/25 Issuer sale

Chief Financial Officer

7,06,588 2.2650%
31/03/25 Issuer sale

Chief Executive Officer

23,85,976 7.6484%
Change 5-day change 1-year change 3-year change Capi.($)
-0.18%-6.52%-51.20%-88.07% 2.54Cr
+10.00%+14.90%+53.89%+87.07% 6.25TCr
+0.80%-5.70%+23.89%+62.65% 5.24TCr
-0.98%-1.19%-16.98%-14.21% 2.31TCr
+0.30%-5.17%-11.23%+349.07% 2.14TCr
+1.73%-1.57%+32.81%-25.80% 1.78TCr
+4.29%+8.97%+200.03%+341.85% 1.55TCr
+1.91%-1.37%+13.35%+611.30% 1.47TCr
+1.71%-0.90%+52.13%+176.27% 1.41TCr
+4.16%+4.44%+444.12%+183.06% 1.26TCr
Average +2.37%+0.24%+74.08%+168.32% 2.34TCr
Weighted average by Cap. +3.64%+1.83%+60.66%+147.23%

Financials

2026 *2027 *
Net sales - 1.29Cr 1.12Cr 1.05Cr 96.14L 1.82Cr 122.96Cr 1.84Cr 12Cr 4.82Cr 61Cr 4.85Cr 4.75Cr 203.67Cr
Net income -2.85Cr -2.47Cr -2.31Cr -2.12Cr -4.01Cr -271.1Cr -4.05Cr -27Cr -11Cr -135.52Cr -11Cr -10Cr -449.03Cr -2.33Cr -2.02Cr -1.88Cr -1.73Cr -3.27Cr -221.33Cr -3.31Cr -22Cr -8.68Cr -110.64Cr -8.74Cr -8.55Cr -366.6Cr
Net Debt - -
Logo Actinium Pharmaceuticals, Inc.
Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company pioneering the development of targeted radiotherapies to address significant unmet medical needs in oncology. It operates a pipeline of both early and later stage development programs with two novel solid tumor product candidates, ATNM-400 and Actimab-A, with pan-tumor potential; Actimab-A, which is also being developed as a therapeutic backbone for acute myeloid leukemia and myelodysplastic syndrome in partnership with the National Cancer Institute (NCI), and two targeted conditioning agents, Iomab-B for bone marrow transplant and Iomab-ACT for cell & gene therapies. Its solid tumor asset, ATNM-400, targets a novel antigen distinct from PSMA, with demonstrated preclinical activity across metastatic castration-resistant prostate cancer (mCRPC), non-small cell lung cancer (NSCLC), and breast cancer. Its hematology franchise includes Actimab-A, Iomab-B and Iomab-ACT, which are CD45-targeting conditioning agents.
Employees
25
Date Price Change Volume
04/26/04 $0.8100 -0.18% 92,119
03/26/03 $0.8115 -3.04% 2,00,148
31/26/31 $0.8369 -0.01% 35,412
30/26/30 $0.8370 +0.01% 26,316
29/26/29 $0.8369 -3.42% 80,795
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.8100USD
Average target price
5.000USD
Spread / Average Target
+517.28%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ATNM Stock